Regenxbio (RGNX) Misses Q2 EPS by 24c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. CVS
8. SWKS
9. SPY
10. XYZ

Go back to Regenxbio (RGNX) Misses Q2 EPS by 24c

REGENXBIO Reports Second Quarter 2021 Financial Results and Operational Highlights

August 9, 2021 4:05 PM EDT

ROCKVILLE, Md., Aug. 9, 2021 /PRNewswire/ --

Enrollment in RGX-314 programs is on-track, including the pivotal program for the treatment of wet AMD utilizing subretinal delivery, and the Phase II trials for the treatment of wet AMD and DR utilizing in-office suprachoroidal delivery Interim data from RGX-314 Phase II trial for the treatment of wet AMD utilizing in-office suprachoroidal delivery will be presented at Retina Society 54th Annual Scientific Meeting Reported additional positive interim data in May 2021 from RGX-121 Phase I/II trial for the treatment of... More